A&M Perspectives: How asset light pharmaceutical companies can augment value creation in a disrupted market environment
Over the past two decades, originator pharmaceutical businesses have increasingly disposed of late-stage drug portfolios to third parties. This has spurred the growth of asset-light pharmaceutical companies with radically different operating models. Operating through networks of Contract Development and Manufacturing Organisations (CDMOs), these businesses avoid major capital expenditure, have greater flexibility, and can therefore focus on critical capabilities such as supply chain excellence, market authorisation and technical transfers.
While there are advantages, asset-light models are complex. Many different partners are involved, comprising of specialised CDMOs, distribution partners and a mix of in-house sales and country distributors. This leads to challenges related to demand planning, inventory control and cost control.
At the same time, asset-light pharma businesses are having to respond to global challenges including rising inflation, supply chain disruptions, Covid-19 outbreaks and growing geopolitical tensions.
Based on our experiences of delivering change for a range of asset-light pharmaceutical companies across Europe, we recommend five levers of value creation.
Five value levers for asset-light pharmaceutical businesses
- CDMO rationalisation and technical transfer excellence
- S&OP/ IBP upgrades
- Inventory and working capital optimisation
- Logistics simplification
- Digital tools deployment (commercial focus)
Download
Related Insights
Shocks to global supply chains are increasing in frequency and severity. Russia’s invasion of Ukraine, new Covid outbreaks in China and rising interest rates in the US are occurring at once with ramifications for global trade. What steps can companies take to improve supply chain resilience.
Building AI from Within at Nebraska Medicine
May 28, 2026
What if the real advantage isn’t buying the latest solution, but building your own? Michael Hasselberg, Chief Transformation and Digital Officer at Nebraska Medicine joins A&M Healthcare Industry Group's Seth Ciabotti and Travis Sherman to share how Nebraska Medicine is building AI capabilities internally—from assembling in-house data science and engineering teams to deploying enterprise tools that address real operational pain points.
Medical Management Is Broken Getting AI Right Will Decide Which Plans Survive
May 7, 2026
AI is reshaping medical management from a cost center into a strategic engine for health plans. In this paper, Managing Directors Bryan Komornik and Craig Savage outline where AI is delivering real value today and how plans can modernize clinical operations to improve cost, quality, and experience.
What’s Your Moonshot? Podcast Series - Episode Briefs
May 6, 2026
In our What’s Your Moonshot? Podcast Series, we seek to uncover big problems in Healthcare and talk to the leaders that are working to solve them.
CareQuest Institute Advancing Access and Affordability in Veterans' Oral Health
May 6, 2026
What if access to oral healthcare was a given—not a barrier—for every veteran? Wade Rakes, Chief Executive Officer of CareQuest Institute for Oral Health joins A&M Healthcare Industry Group's Ken Barrette and David Shulkin, M.D. to share his vision for advancing access, improving affordability, and driving meaningful change in veterans’ oral health.
